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Abstract
Objective: A prospective observational study was performed to assess the epidemiology and clinical impact of
carbapenem-non-susceptible Klebsiella pneumoniae (CNKP) in intensive care units (ICUs) of the national referral
hospital in Jakarta, Indonesia.
Materials/methods: Adult patients consecutively hospitalized for > 48 h in two ICUs of the national referral hospital
were included from April until October 2013 and from April until August 2014. K. pneumoniae from clinical cultures
and standardized screening of rectum and throat on admission, discharge and weekly if hospitalized > 7 days were
collected. Environmental niches and healthcare workers (HCWs) were also screened. Susceptibility was determined
phenotypically and the presence of carbapenemase genes by PCR. Raman spectroscopy as well as multiple-locus
variable number tandem repeat analysis (MLVA) were used for typing.
Results: Twenty-two out of 412 (5.3%) patients carried CNKP on admission and 37/390 (9.5%) acquired CNKP
during ICU stay. The acquisition rate was 24.7/1000 patient-days at risk. One out of 31 (3.2%) environmental isolates
was a CNKP. None of the HCWs carried CNKP. Acquisition of CNKP was associated with longer ICU stay (adjusted
Hazard Ratio: 2.32 [CI99: 1.35–3.68]). ICU survival was lower among patients with CNKP compared to patients with
carbapenem-susceptible K. pneumoniae (aHR 2.57, p = 0.005). Ninety-six of the 100 (96%) CNKP isolates carried a
carbapenemase gene, predominantly blaNDM. Raman typing revealed three major clusters among 48 Raman types
identified, whereas MLVA distinguished six major clusters among a total of 30 different genotypes.
Conclusions: NDM-producing CNKP are introduced into these ICUs and some strains expand clonally among
patients and the environment, resulting in endemic CNKP. CNKP acquisition was associated with prolonged ICU
stay and may affect ICU survival.
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Introduction
Carbapenems are the antibiotics of choice for treatment
of life-threatening infections due to multidrug-resistant
Gram-negative bacilli. However, the worldwide emer-
gence of carbapenem-non-susceptible Klebsiella pneu-
moniae, especially in intensive care units (ICUs), has
become a major challenge. Non-susceptibility to carba-
penems in K. pneumoniae may be due to production of
Ambler class A β-lactamases (e.g. KPC), class B metallo-
β-lactamases (MBLs, e.g. VIM, IMP, NDM) or class D
oxacillinases (e.g. OXA-48 like enzymes) [1–3].
Although carbapenemase-producing K. pneumoniae
have emerged globally, geographic variations do exist.
K. pneumoniae producing KPCs have initially mainly
been reported in the USA and Israel, but more re-
cently also from China and Taiwan [1, 2, 4, 5]. K.
pneumoniae strains carrying OXA-48-like carbapene-
mases were first described in Turkey in 2003. Cur-
rently, K. pneumoniae with OXA-48-like carbapene
mases are spreading rapidly in many European coun-
tries, in addition to being endemic in the Middle East
and in Northern Africa [1, 4, 5]. Bacteria with the
New Delhi metallo-β-lactamase (NDM) enzyme, which
was first identified in Sweden from a patient who had
travelled from New Delhi, India, have attained en-
demic levels in countries of the Indian subcontinent
including India, Pakistan, Bangladesh and Sri Lanka
[1, 4–8]. This gene is also encountered in bacteria,
including K. pneumoniae, in some countries in the
South East Asian region, including Singapore [9],
Thailand [10] and Vietnam [1]. However, so far there
have been few data on the epidemiology of
carbapenem-non-susceptible K. pneumoniae reported
from Indonesia, the fourth most populous country in
the world. In 2011, 27.6% of the Enterobacteriaceae
isolated from specimens at two ICUs in Jakarta was
carbapenem-resistant, including one K. pneumoniae
harboring the blaNDM gene [11]. In 2014–2015, the
prevalence of resistance to meropenem among K.
pneumoniae from urinary tract infections in clinical
and outpatient clinical settings was 14.0%, but no fur-
ther analysis of these isolates was performed [12].
The aim of the present study was to delineate the
clinical and molecular epidemiology of carbapenem-
non-susceptible K. pneumoniae isolated in two ICUs
of the Dr. Cipto Mangunkusumo General Hospital,
the national referral teaching hospital in Jakarta.
Materials and methods
Study design
A prospective observational study was performed in
a 1000-bed national referral teaching hospital with
34,000 admissions per year in Jakarta, Indonesia,
from April until October 2013 and from April until
August 2014. Two ICUs participated, the adult ICU
and the Emergency Room (ER)-ICU, with 865 and
390 admissions in 2013, respectively, and 1154 and
439 admissions in 2014, respectively. The adult ICU
is a 12-bed open ward with mechanical ventilation
facilities, admitting patients with various medical and
surgical indications, and one designated nurse per
patient during morning shifts and a 1:1.5 nurse/pa-
tient ratio during other shifts. It is also used as
post-anaesthetic care unit. The ER-ICU has the same
design, but 8 beds, and the nurse per patient ratio in
the morning shifts is 1:1 and during the other shifts
1:2. This ICU is also used for short observations.
All adult patients (≥18 years old) admitted to one
of the two ICUs and hospitalized for more than 48 h
were eligible for enrollment in this study. Informed
consent was obtained from the patient or their rela-
tives as applicable. Demographic and clinical charac-
teristics such as age, gender, medical or surgical
indication, underlying diseases, hospitalization his-
tory, and previous use of antibiotics on admission
were recorded.
Systemic inflammatory response syndrome (SIRS)
criteria on admission were used as a screening tool
to assess (severity of) septic illness. The “Acute
Physiology and Chronic Health Evaluation II” score was
not feasible in this low-resource setting. SIRS is defined as
two or more of the following: fever > 38 °C or < 36 °C, heart
rate > 90 beats per minute, respiratory rate > 20 breaths per
minute or PaCO2 < 32mmHg, abnormal white blood cell
count (> 12,000/mm3 or < 4000/mm3 or > 10% bands) [13].
The quick Sequential Organ Failure Assessment
(qSOFA) score is a newer bedside prompt that may
identify patients with suspected infection and helps
to determine sepsis in all healthcare environments.
The qSOFA score assigns one point for each of the
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following conditions: systolic blood pressure ≤ 100
mmHg, respiratory rate ≥ 22 breaths per minute, and
altered mentation (Glasgow coma scale < 15). The
score ranges from 0 to 3 points. A qSOFA score ≥ 2
at the onset of infection is associated with a greater
risk of death and prolonged ICU stay. This score
was included as well [13].
Acquisition is defined as a screening culture (throat
or rectum/stool) or clinical culture with a first detec-
tion of K. pneumoniae with reduced susceptibility to
a carbapenem, that was not present in cultures taken
from the patient on admission or in the first 48 h of
admission. Outcome measures were acquisition of a
carbapenem-susceptible and carbapenem-non-susc
eptible K. pneumoniae (independent of resistance to
other classes of antibiotics), length of stay in the ICU,
and mortality during ICU stay.
Environmental samples were taken twice (in Octo-
ber 2013 and December 2014), simultaneously in
both ICUs. Screening of healthcare workers (HCWs)
was performed once. HCWs were defined as all
personnel including doctors, nurses and other people
(cleaning staff, administration staff, porters, nutri-
tionist) working in one of the two ICUs during the
study period.
Sampling
From patients enrolled, screening cultures were ob-
tained from throat and rectum or stools by experi-
enced ICU nurses on the day of admission, at the
time of discharge from the ICU, and weekly if the
patient was admitted for seven days or more. The
samples were collected with sterile cotton-tipped
swabs and placed in Amies transport medium
(Oxoid, Basingstoke, UK). The swabs were trans-
ported in clean, closed boxes at ambient temperature
to the laboratory on the same day. All swabs were
processed in the laboratory within 24 h.
Clinical samples were collected from a patient when
the ICU physician suspected the patient of having an
infection. Specimens were taken under aseptic precau-
tions from the lower respiratory tract, blood, urine,
tissue, or wound, on indication.
Environmental samples were taken from various
sites, including wash basins, bed rails, bedside cabinet
tables, ventilators, and monitor screens (Supplemen-
tary Table 1), with sterile cotton-tipped swabs and
placed in Amies transport medium [14].
All HCWs working in one of the ICUs were sam-
pled (rectal and throat) once over the course of one
month (September 2013) with sterile cotton-tipped
swabs, which were transported to the laboratory in
Amies transport medium.
Microbiological methods
Isolation and identification of bacteria
In the laboratory, each screening swab was placed in a
trypticase soy broth (TSB) supplemented with cefotax-
ime 2mg/L plus vancomycin 50mg/L and incubated
overnight. The next day, a loop of broth was sub-
cultured on MacConkey agar (Oxoid).
Blood cultures were collected in BACTEC (BD, Frank-
lin Lakes, NJ, USA) bottles as per manufacturer’s in-
structions with a minimum of 10 mL of blood collected
from at least two puncture sites. Other clinical speci-
mens were inoculated onto blood and MacConkey agar
plates (Oxoid) and incubated for 24 h at 37 °C. All mor-
phologically different colonies were examined by Gram
stain and identified using the VITEK2® system (bioMér-
ieux, Lyon, France).
Strains were stored in duplicate in − 80 °C in TSB
with glycerol 10%. One tube of each strain was sent
to the Department of Medical Microbiology and In-
fectious Diseases, Erasmus MC, Rotterdam, the
Netherlands, for further analysis. The other tube of
each strain remained in the Indonesian laboratory. In
the Netherlands, the identity of strains was confirmed
using matrix-assisted laser desorption/ionisation
(Maldi Biotyper, Bruker Microflex LT, Bruker,
London, UK).
The quality control strains used for this part of the
study in Indonesia were Escherichia coli ATCC 25922
and Pseudomonas aeruginosa ATCC 27853, in the la-
boratory of Erasmus MC multiple quality control strains
were used.
Antimicrobial susceptibility testing
Imipenem and meropenem susceptibility tests on isolates
from screening cultures were performed by standard Kirby-
Bauer disc diffusion technique using Mueller-Hinton agar
plates (BD) based on EUCAST Disc Diffusion Method for
Antimicrobial Susceptibility Testing- Version 3.0 (April
2013). Minimum inhibitory concentrations (MICs) of anti-
biotics were determined by VITEK2® for clinical isolates.
Carbapenem MICs and zone sizes were interpreted accord-
ing to EUCAST (2013) using the following breakpoints for
non-susceptibility: meropenem > 0.25mg/L (< 24mm), imi-
penem > 1mg/L (< 22mm) [15].
For this part of the study, quality control strains as de-
scribed above were used.
String test
In order to determine hyper-muco-viscosity, the string
assay was performed for all K. pneumoniae isolates. For
this, the strains were inoculated onto 5% sheep blood
agar (BD) and kept overnight at 37 °C. An individual col-
ony was then touched with a 1 μL disposable loop which
was subsequently pulled up slowly. The string test was
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deemed positive if a string of ≥5 mm was formed be-
tween the colony and the loop [16].
Phenotypic detection of carbapenemase
A phenotypic detection test for Ambler class A and B
and OXA-48-like carbapenemases was performed with
discs (Rosco Diagnostica A/S, Taastrup, Denmark) con-
taining meropenem (10 μg), temocillin (30 μg), merope-
nem + phenyl boronic acid (PBA), meropenem +
dipicolinic acid (DPA), meropenem + PBA +DPA, and
meropenem + cloxacillin (CL), using a 0.5 McFarland sus-
pension of the isolates on Mueller Hinton II agar plates.
Zone diameters were measured after overnight incubation
at 37 °C. The temocillin zone diameter was only inter-
preted if no synergy was observed with DPA and/or PBA.
Isolates without synergy with the PBA or DPA test and a
temocillin zone diameter ≤ 10mm (i.e. the absence of an
inhibition zone around the temocillin disc) were consid-
ered OXA carbapenemase positive. The interpretation of
the PBA and DPA synergy tests and the temocillin disc
diffusion were as described previously [17].
DNA extraction and PCR for carbapenemase genes
DNA from the isolates was extracted by a cell lysis step
and boiling using the InstaGene Matrix (Bio-Rad La-
boratories, USA) according to the manufacturer’s in-
structions. PCR-based detection of Ambler class A
carbapenemases (blaKPC), Ambler class B metallo-β-
lactamases (blaNDM), and class D β-lactamases
(blaOXA-48-like) were carried out using T3000 Thermocy-
cler (Biometra-Whatman, Goettingen). PCR primers and
reaction conditions for PCR were as described previously
[18–20]. Amplified PCR products were resolved by elec-
trophoresis at 250 V for 30 min on 1.5% agarose gels
with 0.5 x Tris (89 mM)-boric acid (89 mM)-EDTA (2
mM) buffer containing SyBr® Safe DNA Gel Stain and
visualized under UV light and photographed. In each
run, a positive and negative control was included.
Clonal relatedness
Raman spectroscopy (SpectraCell RA® Bacterial
Strain Analyzer, RiverD International BV, Rotterdam,
The Netherlands) was applied as a first typing
method [21, 22]. All isolates were grown overnight
on trypticase soy agar (TSA; BD). Samples were pre-
pared and submitted to spectrometry as described
previously [22]. Raman light scatterings were ana-
lyzed by SpectraCellRA software version 1.9.0.13444:
24 (RiverD). The similarity between pairs of spectra
was calculated using the squared Pearson correlation
coefficient (R2-values), multiplied by 100 and
expressed as a percentage. The similarity threshold
for this study was set at 91% so that two isolates
with an R2 below this threshold were considered to
be different and were designated different Raman
types. Two isolates with an R2-value above 99.5%
were considered indistinguishable and were consid-
ered to have the same Raman type. In case of an R2-
value between of 91 and 99.5%, these isolates were
considered highly related but not identical [23].
Correlation matrices displayed as 2D plots diagram
were created using MATLAB version 7.1 (The Math-
Works, Natick, MA, USA).
Multiple-locus variable number tandem repeat analysis
(MLVA) was used as a second typing method. The
MLVA typing protocol was based on Brink et al. [24]
with minor modifications (for details, see Supplement).
DNA was quantitated using PicoGreen dsDNA reagent
(Invitrogen, Bleiswijk, The Netherlands). Amplification
reactions contained approximately 1 ng of DNA and
primers according to Supplementary Table 2 in 1x
Roche FastStart PCR Master Mix (Roche diagnostics, Al-
mere, The Netherlands). The thermocycling protocol
consisted of an initial denaturation for 5 min at 95 °C
followed by 30 amplification cycles of denaturation for
30s at 95 °C, 30s annealing at 58 °C and 1min extension
at 72 °C. A final extension step of 30 min at 72 °C was
applied before reactions were cooled to room
temperature. Before loading, amplification products were
diluted 100x, combined with the GeneScan 600 LIZ Dye
Size Standard (ThermoFisher Scientific, Bleiswijk, The
Netherlands) and run on an ABI 3130 capillary electro-
phoresis platform (ThermoFisher Scientific) using rec-
ommended conditions. Electropherograms were
analyzed using the MLVA plugin in BioNumerics v7.6
software (Applied-Maths, Sint-Martens-Latem, Belgium).
Assignment of repeat numbers was calibrated by com-
paring our results to those obtained with selected iso-
lates that were genotyped by the Maastricht lab. Typing
data was analyzed categorically.
Statistical analysis
Statistical analyses were performed using SPSS Version
24.0 (SPSS, Chicago, IL, USA). Baseline characteristics
from patients admitted to the adult ICU were compared
to those in the ER-ICU using Chi square and Mann-
Whitney as appropriate. One-way ANOVA was used to
compare patient characteristics according to their K.
pneumoniae status. Univariate and multivariate analyses
were performed to establish risk factors associated with
in-ICU mortality using a multivariate logistic regression
model with backward selection and inclusion of variables
with a p value < 0.1 in the univariate analysis. Cox pro-
portional regression was used to analyze risk factors for
length of stay. Kaplan-Meier method was performed to
construct survival curves. The R-code (R-3.6.2.pkg. bin-
ary for OS X 10.11 software can be obtained via CRAN,
the Comprehensive R Archive Network, http://cran.R-
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project.org) was used to calculate the competing risks
estimates (competing risk analysis is available in an add-
on package called cmprsk) of the cumulative incidence
function and conditional probability function for ICU
discharge and in-ICU mortality [25, 26]. P values less
than 0.01 were considered significant [27].
Results
Patient characteristics and outcomes
During the 11-month study period, 1211 patients were
hospitalized in the ICUs (Adult ICU: 863, ER-ICU: 348).
Of the 412 included patients, 188 were admitted to the
adult ICU and 224 to the ER-ICU. Supplementary
Table 3 shows baseline characteristics of included pa-
tients in each ICU. There were no significant differences
in characteristics between patients in both ICUs, except
that in the adult ICU most of the patients had been re-
ferred from another ward in the same hospital and the
proportion of patients with malignancies was higher.
Therefore, we analyzed the data from the ICUs both sep-
arately and pooled.
Overall, 192/412 (46.6%) patients had at least one posi-
tive culture with K. pneumoniae, the remaining 220 pa-
tients were free from K. pneumoniae on admission and
remained so during their ICU stay. One hundred (24.3%)
patients already carried K. pneumoniae on the day of ad-
mission, of whom 78 carried a carbapenem–susceptible
K. pneumoniae and 22 (5.3%) carried a carbapenem-
non-susceptible K. pneumoniae strain (Supplementary
Figure 1). One hundred patients (32.1%) acquired K.
pneumoniae during ICU stay, a carbapenem-non-
susceptible K. pneumoniae strain in 37 cases and a
carbapenem-susceptible strain of K. pneumoniae by 63
patients. Thus, a total of 59 patients (14.3%) carried a
carbapenem-non-susceptible K. pneumoniae at a certain
moment during their ICU stay. In 44 patients, this K.
pneumoniae was only found in a screening culture, in
five patients only from a clinical specimen, and in ten
patients from both screening and clinical samples.
The dynamics of acquisition of K. pneumoniae in the
ICUs is shown in Fig. 1. Patients that acquired a
carbapenem-susceptible K. pneumoniae had their first
positive culture approximately four days sooner than pa-
tients that acquired a carbapenem-non-susceptible strain
of K. pneumoniae (p < 0.001). However, the acquisition
rate of carbapenem-susceptible K. pneumoniae was
higher with 41.0 per 1000 patient-days at risk (adult
ICU: 46.1; ER-ICU: 35.9) compared to the acquisition
rate of carbapenem-non-susceptible K. pneumoniae that
was 24.7 per 1000 patient-days at risk (adult ICU: 22.2;
ER-ICU: 27.0).
Patient outcomes were clearly associated with K. pneu-
moniae status. Patients who acquired carbapenem-non-
susceptible K. pneumoniae during ICU stay had a
Fig. 1 Rate of acquisition of carbapenem-susceptible and -non-susceptible K. pneumoniae in ICUs. Acquisition dynamics of carbapenem-
susceptible and –non-susceptible K. pneumoniae during ICU stay. The blue line represents the cumulative percentage of patients by first day of
culture being positive for carbapenem-susceptible K. pneumoniae during ICU stay. The red line represents the cumulative percentage of patients
by first day of culture being positive for carbapenem-non-susceptible K. pneumoniae during ICU stay. P value was calculated using independent
samples-Mann Whitney U test. In total, data from 100 patients are included in this figure
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significantly longer length of stay (median [interquartile
range (IQR)]: 11 [8–20] days, adjusted Hazard Ratio
[aHR]: 2.32 [99% confidence interval (CI): 1.35–3.68],
p < 0.001, Fig. 2 and Supplementary Table 4) compared
to the other groups of patients, of whom ≥80% were dis-
charged from the ICU within 2–13 days. Interestingly,
these latter groups included the patients that were al-
ways free from K. pneumoniae, and patients that already
carried K. pneumoniae (either carbapenem-susceptible
or carbapenem-non-susceptible) at the time of admis-
sion to the ICU and patients who became positive for
carbapenem-susceptible K. pneumoniae during their stay
in ICU (Fig. 2).
A longer length of stay was also associated with mech-
anical ventilation ≥5 days (median [IQR]: 10 [7–15],
aHR: 2.79 [CI99]: 1.80–4.34], p < 0.001, Supplementary
Table 4) and use of a urinary catheter ≥5 days (median
[IQR]: 8 [5–12], aHR: 3.88 [CI99: 2.14–7.04], p < 0.001,
Supplementary Table 4) during ICU stay.
However, the acquisition of K. pneumoniae was not as-
sociated with in-ICU mortality, 30.5% of patients that
remained free of K. pneumoniae died versus 17.5 and
43.2% of patients that acquired a carbapenem-
susceptible or non-susceptible K. pneumoniae strain, re-
spectively, during their ICU stay (Supplementary Table 5,
adjusted Odds Ratio [aOR]: 0.40 [99% CI: 0.14–1.13],
p = 0.023 and 1.03 [0.36–2.97], p = 0.937). Interestingly,
the group of patients that carried a carbapenem-
susceptible strain of K. pneumoniae, either on admission
or acquired during ICU stay, had the lowest observed
Fig. 2 Cumulative percentage of length of stay according to K. pneumoniae status. Cumulative length of ICU stay of patients based on their K.
pneumoniae status. Length of stay (days) represent total days patients were hospitalized in the ICU. The blue line represents patients that were
always K. pneumoniae negative during their ICU stay. The red line represents patients already positive for carbapenem-susceptible K. pneumoniae
on the day of admission. The green line represents patients already positive for carbapenem-non-susceptible K. pneumoniae on the day of
admission. The orange line represents patients that acquired carbapenem-susceptible K. pneumoniae during ICU stay and the black line
represents patients that acquired carbapenem-non-susceptible K. pneumoniae during ICU stay. The length of stay of patients that became positive
with carbapenem-non-susceptible K. pneumoniae during ICU stay was longer than that of the other groups (Cox regression, P < 0.001)
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mortality rates (24.3 and 17.5%, respectively), even lower
than the 30.5% mortality observed among those patients
that were always negative for this species, but this differ-
ence did not reach statistical significance. However, when
compared to patients that had a carbapenem-non-
susceptible isolate of K. pneumoniae, either on admission
or during their ICU stay, the ICU survival of patients with
carbapenem-susceptible strains was significantly higher
(aHR: 2.57 [99% CI: 1.07–6.17], p = 0.005, Fig. 3). Import-
antly, the admission SIRS and qSOFA scores of patients
with or without K. pneumoniae acquisition did not differ
(Table 1), indicating that a difference in the risk of dying
was not present at the time of ICU admission but emerged
later during their ICU stay (SIRS: crude Odds Ratio
[cOR]: 1.69 [99% CI: 0.55–5.22], p = 0.230; qSOFA: cOR:
1.45 [99% CI: 0.68–3.08], p = 0.211, Supplementary
Table 5).
The competing risk estimates analysis also revealed
that the incidence of death was higher in patients
with a carbapenem-non-susceptible isolate of K. pneu-
moniae (p = 0.006), and the incidence of being dis-
charged alive from ICU was higher for patients with a
carbapenem-susceptible K. pneumoniae (p = 0.0005)
(Supplementary Figure 2). Patients that acquired a
carbapenem-non-susceptible K. pneumoniae during
ICU stay were more likely to have had prior exposure
to antibiotics, especially carbapenems, and they were
more likely to have had a medical indication for their
admission to the ICU (Table 1).
Phenotypic and molecular characterization of
carbapenem-non-susceptible K. pneumoniae
Overall, 99/370 (26.8%) isolates from 59/192 (30.7%) pa-
tients were found to be non-susceptible to carbapenems.
In addition, one (water from suction connector) out of
31 K. pneumoniae isolates cultured from the environ-
ment (400 samples taken) was carbapenem-non-
susceptible. None of 24 K. pneumoniae isolates cultured
from HCWs (out of 167 screened) were found to be
carbapenem-non-susceptible. Thus, a total of 100
carbapenem-non-susceptible isolates was further sub-
jected to phenotypic and molecular analyses. The pheno-
typic detection test indicated that 96/100 (96%) isolates
produced a MBL. PCRs of carbapenemase genes demon-
strated the presence of the blaNDM gene in these 96
carbapenem-non-susceptible isolates, including isolates
from patients and the one from the environment. None
of the 100 isolates was positive for either the blaKPC or
blaOXA-48 gene. Four carbapenem-non-susceptible
strains apparently contained another resistance mechan-
ism, which was not further investigated, they remained
relatively susceptible to carbapenems (MIC meropenem
2–4 mg/L). The string test was positive for only four iso-
lates from three patients, one of whom deceased in ICU.
Clonal relatedness
Raman spectroscopy analysis performed for 100 iso-
lates revealed the presence of multiple types within
Fig. 3 Survival of patients according to their K. pneumoniae status. Survival of patients with carbapenem-non-susceptible K. pneumoniae (on
admission or acquired during ICU stay) (red line) compared with the survival of patients that had carbapenem-susceptible K. pneumoniae (on
admission or acquired during ICU stay) (blue line) in their screening and/or clinical cultures. P value was calculated using logistic regression
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Table 1 Patient characteristics and outcomes according to their Klebsiella pneumoniae status
Group 1 Group 2 Group 3 Group 4 Group 5 p value
220 70 22 63 37
Age (years), median (IQR) 46 (33–58) 49 (33–58) 31.5 (25–49) 50 (38–58) 47 (35.5–62) 0.036
Gender (%) 0.533
Male 108 (49.1) 35 (50) 13 (59.1) 35 (55.6) 23 (62.2)
Female 112 (50.9) 35 (50) 9 (40.9) 28 (44.4) 14 (37.8)
Underlying diseases (%)
Cardiovascular 0.556
Yes 10 (4.5) 64 (91.4) 1 (4.5) 5 (7.9) 3 (8.1)
No 210 (95.5) 6 (8.6) 21 (95.5) 58 (92.1) 34 (91.9)
Cerebrovascular 0.026
Yes 11 (5.0) 2 (2.9) 3 (13.6) 8 (12.7) 5 (13.5)
No 209 (95.0) 68 (97.1) 19 (86.4) 55 (87.3) 32 (86.5)
Chronic kidney disease 0.068
Yes 17 (7.7) 7 (10.0) 0 1 (1.6) 0
No 203 (92.3) 63 (70.0) 22 (100) 62 (98.4) 37 (100.0)
Diabetes mellitus 0.138
Yes 12 (5.5) 10 (14.3) 1 (4.5) 6 (9.5) 4 (10.8)
No 208 (94.5) 60 (85.7) 21 (95.5) 57 (90.5) 33 (89.2)
Malignancy 0.717
Yes 68 (30.9) 20 (28.6) 4 (18.2) 16 (25.4) 10 (27.0)
No 152 (69.1) 50 (71.4) 18 (81.8) 47 (74.6) 27 (73.0)
Indication for ICU admission (%) 0.005
Medical 64 (29.1) 21 (30.0) 10 (45.5) 23 (36.5) 22 (59.5)
Surgical 156 (70.9) 49 (70.0) 12 (54.5) 40 (63.5) 15 (40.5)
Referral from (%) 0.378
Other ward this hospital 115 (52.3) 36 (51.4) 15 (68.2) 33 (52.4) 23 (62.2)
Other hospital 40 (18.2) 14 (20.0) 2 (9.1) 11 (17.5) 10 (27.0)
Directly from Emergency Unit 65 (29.5) 20 (28.6) 5 (22.7) 19 (30.2) 4 (10.8)
Antibiotic exposure (pre-ICU admission)
Any antibiotic (%) 163 (74.1) 54 (77.1) 18 (81.8) 44 (69.8) 32 (86.5) 0.365
Carbapenem (%) 44 (20.0) 3 (4.3) 7 (31.8) 12 (19.0) 13 (35.1) < 0.001
SIRS Score, (%) 0.598
Score > 2 200 (91.0) 63 (70.0) 22 (100.0) 59 (93.7) 33 (89.2)
Score < 2 20 (9.0) 7 (10.0) 0 4 (6.3) 4 (10.8)
qSOFA Score, (%) 0.971
Score ≥ 2 179 (81.4) 56 (80.0) 17 (77.3) 51 (81.0) 31 (83.2)
Score < 2 41 (18.6) 14 (20.0) 5 (22.7) 12 (19.0) 6 (16.2)
Procedures (during ICU admission)
Mechanical ventilation used (%) 199 (90.5) 59 (84.3) 20 (90.9) 57 (90.5) 36 (97.3) 0.314
Mechanical ventilation (days) < 0.001
≥ 5 days 74 (33.6) 30 (42.9) 12 (54.5) 34 (54.0) 32 (86.5)
< 5 days 146 (66.4) 40 (57.1) 10 (45.5) 29 (46.0) 5 (13.5)
Central venous catheter used (%) 193 (87.7) 62 (88.6) 19 (86.4) 53 (84.1) 36 (97.3) 0.343
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this collection of K. pneumoniae. In total, 48 Raman
types were identified. There were three major clusters
(Supplementary Figure 3), the largest cluster (CIP-
TOKPN24) consisted of 20 isolates obtained from 13
patients (screening and clinical specimens). Strains
belonging to the dominant cluster CIPTOKPN24 were
present in both ICUs throughout the study period,
whereas other clones seemed to wax and wane with
time (Fig. 4).
A total of 97 clinical (two isolates were lost during
storage) and 1 environmental isolate were further an-
alyzed using MLVA genotyping, identifying 30 differ-
ent genotypes (Fig. 5). The most dominant clone
accounted for 26.5% (n = 26) of all isolates, whereas
19 isolates (19.4%) were of a unique genotype, the
remaining 53 isolates belonged to 20 other genotypes.
Clustering of strains by Raman spectroscopy into
three dominant groups was concordant with cluster-
ing by MLVA, e.g. the 20 Raman CIPTOKPN24
strains all belonged to a single MLVA clonal complex.
Likewise, the four Raman CIPTOKPN30 strains
belonged to a single MLVA clonal complex as did 8/
10 CIPTOKPN27 isolates.
Discussion
This is the first report of a study on the clinical and
molecular epidemiology of carbapenemase-producing
K. pneumoniae in ICUs in Indonesia. These two ICUs
can be considered to have endemic carbapenem-non-
susceptible K. pneumoniae whose acquisition by pa-
tients is associated with prolonged ICU stay and, pos-
sibly, an increased risk of dying.
The dissemination of K. pneumoniae isolates harboring
carbapenemase genes, continues unabated, and reports
describing these isolates are emerging from different parts
of the world, including Southeast Asia [1, 4, 28].
Colonization and infection with carbapenem-resistant K.
pneumoniae has been reported in Singapore [29]. In
Malaysia, the National Surveillance of Antimicrobial re-
sistance found carbapenem resistance rates among K.
pneumoniae to increase from 0.5% (11,935 isolates tested)
in 2010 to 1.6% (27,911 isolates tested) in 2014 [30]. The
Philippines Department of Health’s Research Institute re-
ported a rate of 11.9% in 2015 [30]. Morocco [31], Italy
[32], and India have likewise shown dramatic increases
over time [30]. Similar to these studies, we found that 59/
412 (14.3%) of the patients in the ICU carried a
carbapenem-non-susceptible K. pneumoniae. By screening
on ICU admission 5.3% of patients were already colonized
with carbapenem-non-susceptible K. pneumoniae prior to
their admission to the ICU. This suggests that patients
may become colonized with such strains elsewhere in the
same hospital or in another hospital from which they are
referred, or may come with such strain directly from the
Table 1 Patient characteristics and outcomes according to their Klebsiella pneumoniae status (Continued)
Group 1 Group 2 Group 3 Group 4 Group 5 p value
220 70 22 63 37
Central venous catheter (days) < 0.001
≥ 5 days 96 (43.6) 40 (57.1) 12 (54.5) 42 (66.7) 33 (89.2)
< 5 days 124 (56.4) 30 (42.9) 10 (45.5) 21 (33.3) 4 (10.8)
Urinary catheter (%) 220 (100.0) 70 (100.0) 22 (100.0) 63 (100.0) 37 (100.0) NA
Urinary catheter (days) median (IQR)
≥ 5 days 112 (50.9) 44 (62.9) 15 (68.2) 46 (73.0) 34 (91.9) < 0.001
< 5 days 108 (49.1) 26 (37.1) 7 (31.8) 17 (27.0) 3 (8.1)
Antibiotic therapy (during ICU admission)
Any antibiotic (%) 217 (98.2) 70 (100.0) 21 (95.5) 62 (98.4) 36 (100.0) 0.474
Carbapenem (%) 110 (49.8) 26 (37.1) 13 (59.1) 29 (46.0) 21 (58.3) 0.179
Outcomes
Length of stay (days), median (IQR) 4 (2–6) 5 (3–9) 6 (3–13) 7 (4–13) 11 (8–20) < 0.001
Death (%) 67 (30.3) 17 (24.3) 8 (36.4) 11 (17.5) 16 (44.4) 0.054
Abbreviations: ICU Intensive Care Unit; IQR Interquartile range; NS Non-Susceptible; qSOFA quick Sepsis-related Organ Failure Assessment; SIRS Systemic
Inflammatory Response Syndrome; S Susceptible
Group 1: No K. pneumoniae on admission and negative for K. pneumoniae during ICU admission
Group 2: Carbapenem-S K. pneumoniae on admission, no carbapenem-NS K. pneumoniae acquisition during ICU admission
Group 3: Carbapenem-NS K. pneumoniae on admission, considered as positive during ICU admission (regardless of results of follow-up cultures)
Group 4: No K. pneumoniae on admission, acquisition of carbapenem-S K. pneumoniae during ICU admission
Group 5: Either no K. pneumoniae or carbapenem-S K. pneumoniae on admission, acquisition of carbapenem-NS K. pneumoniae during ICU admission
Significance was calculated using One-way ANOVA, Pearson Chi Square and Fisher’s Exact Test
A p-value less than 0.01 was considered statistically significant
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Fig. 5 MLVA minimum spanning trees of carbapenem-non-susceptible Klebsiella pneumoniae. Minimum spanning tree analysis of K. pneumoniae
isolates based on clustering at the VNTR loci. Clusters of genotypes differing in only one marker are indicated with a grey background. Panel a:
Colours correspond to specimens from which K. pneumoniae isolates were cultured. Panel b: Distribution of genotypes per patient. Each colour,
except white, indicates a different patient. Only patients with 2 or more isolates are presented in this manner. Patients that had only one isolate
of a carbapenem-non-susceptible K. pneumoniae are indicated by the colour white
Fig. 4 Persistence of prevalent clones of carbapenem-non-susceptible K. pneumoniae in ICUs, as determined by Raman spectroscopy typing.
Endemicity of the three largest clusters, as determined by Raman spectroscopy, of carbapenem-non-susceptible K. pneumoniae in ICUs, April–
October 2013 and April–August 2014. The orange bars represent cluster CIPTOKPN24. The blue bars represent CIPTOKPN27. The green bars
represent CIPTOKPN30. The x-axis indicates time periods of the study (by week, April 2013-Oktober 2013 and April 2014–August 2014). The y-axis
indicates number of isolates
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community, possibly having acquired their strain during a
previous healthcare contact or indirectly from exposure to
reservoirs or relatives carrying such strains [33].
Screening cultures can, therefore, be considered
helpful for early detection and infection control. It
may also be useful to guide rational antibiotic use,
since previous studies have shown that colonization
with a carbapenem-resistant K. pneumoniae is a risk
factor for subsequent infection [34, 35]. However,
during our study, carbapenem-non-susceptible K.
pneumoniae strains were not isolated from blood
cultures (data not shown).
Our data also show that patients may acquire
carbapenem-non-susceptible K. pneumoniae during
ICU stay in the setting of our study and that these
acquisitions are associated with significantly longer
ICU stay. At the level of significance chosen, the ac-
quisition of K. pneumoniae strains, whether carba-
penem susceptible or not, was not associated with
mortality when compared to patients who remained
free of K. pneumoniae. In contrast, the study from
Dautzenberg et al. (2015) showed patients colonized
with carbapenemase-producing Enterobacteriaceae to
have on average a 1.79 times higher hazard of dying
in ICU than non-colonized patients, primarily because
of an increased length of stay [36]. A study in
Singapore reported that cases with carbapenem-
resistant strains of Enterobacteriaceae had ~ 3.5 times
increased odds of fatality adjusted for length of hos-
pital stay [29].
Interestingly, our study shows that the risk of
dying among ICU patients who were culture-positive
for carbapenem-non-susceptible K. pneumoniae on
admission or during ICU stay was significantly, 2.57
times, higher than among patients who were culture-
positive for a carbapenem-susceptible K. pneumo-
niae. The observed ICU fatality rates were indeed
highest (44.4%) among those acquiring carbapenem-
non-susceptible K. pneumoniae and lowest (17.5%)
amongst the patients acquiring carbapenem-
susceptible strains of K. pneumoniae during their
ICU stay. Since risk of mortality during ICU stay is
influenced by many factors, as reported by other
international findings [32, 37, 38], we cannot readily
explain why susceptible K. pneumoniae acquisitions
seem to be a proxy for protection whereas non-
susceptible K. pneumoniae acquisitions may be pre-
dictive of a fatal outcome. Probably, exposure to car-
bapenem antibiotics, and the underlying reasons for
this, may be important determinants in this respect.
The blaNDM gene was the most prevalent carbapene-
mase gene as it was detected in 96 isolates, including
one from the environment. Carbapenem resistance due
to blaKPC-like and blaOXA-48-like genes was not detected.
In South Asia (India and Pakistan) the NDM-1 gene was
initially found and currently, this enzyme is by far the
most prevalent and widely distributed carbapenem de-
grading enzyme in the world, including in Southeast
Asia [1, 3–6, 8–10, 18, 28–31].
Walsh et al. (2011) have also found the presence
of NDM-1 β-lactamase-producing bacteria, including
K. pneumoniae, from waste seepages samples in In-
dian community [33]. Taking our study and the re-
cent report on NDM-1 in carbapenem-non-susceptible
Enterobacteriaceae from urinay tract samples of hospi-
talized patients in Surabaya, Indonesia, into account,
we suspect that this carbapenemase gene is wide-
spread in hospitals in Indonesia [39].
Carbapenem-susceptible and -non-susceptible K.
pneumoniae that colonize or infect ICU patients may
originate from the patient her/himself, but may also
come from contaminated hospital equipment and en-
vironment, staff and other patients. In this study K.
pneumoniae was found in the ICU environment, in-
cluding one endemic strain that was carbapenem-
non-susceptible. Predictably, K. pneumoniae was also
cultured from throat and rectal swabs of ICU
personnel, although none of those isolates was
carbapenem-non-susceptible. However, we cannot
exclude personnel as a source or vector of K. pneu-
moniae since personnel was only screened once dur-
ing this study and other body parts (e.g. hands) or
clothes were not sampled, limiting the sensitivity of
this part of the survey. A recent study in China
found that almost 9% of medical personnel in ICU
carried multidrug-resistant Gram-negative bacteria
on their hands [40]. Transmission of the bacteria
may occur with many risk factors involved [1, 3, 41].
Multiple studies reported outbreaks of carbapenem-
resistant K. pneumoniae that were associated with
environmental contamination [42–44]. We performed
Raman spectroscopy and MLVA to assess clonal re-
latedness. These analyses revealed three major clus-
ters by Raman typing, with the largest one
(CIPTOKPN24), persisting in both ICUs throughout
the whole study period. However, many carbapenem-
non-susceptible strains of K. pneumoniae cultured in
this study were of a unique Raman type or belonged
to small clusters that waxed and waned quickly, indi-
cating both endemicity of certain clones in the ICUs
but also regular new introductions and rapid loss of
many clones over time. This epidemiologic informa-
tion can and should be applied when designing in-
terventions to reduce the acquisition of carbapenem-
resistant K. pneumoniae in ICUs in Indonesia and in
similar settings elsewhere.
Although not used routinely, Raman spectroscopy
typing can be valuable for discriminating types of
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strains within a species [21–23]. Here we showed
typing by Raman spectroscopy to yield K. pneumo-
niae strain clustering compatible with clustering
based on MLVA genotyping. However, Raman typing
results at a given site cannot be directly compared
with results generated or published elsewhere, and
are, thus, not easily shared or pooled. Considering
the modification that we made to MLVA marker
VNTR58, the genotype of the most dominant clone
in our study was of genotype “4–2.4–3-4-4.3–1–12-
19”. This genotype would translate into “4–3–3-4-5-
1-12-19” based on the original MLVA typing method
for K. pneumoniae [24], but this genotype was not
observed by Brink et al. [24]. On the other hand, the
second and third most dominant genotype “5–3–3-4-
6-1-9-12” and “5–3–3-5-6-1-9-12” match genotype
“5–3–3-4-6-1-9-1” and a single locus variant thereof
from Brink et al. that involves isolates with MLST
sequence type ST147. K. pneumoniae ST147 strains
belong to a relatively common NDM-positive K.
pneumoniae lineage and have been found in multiple
countries across several continents, almost all of
which were isolated from humans [45, 46]. Unlike in
the original paper, in our approach the non-integer
alleles were considered as separate alleles. As a re-
sult, the total number of alleles per marker will in-
crease for several markers and as a result this may
benefit the overall discriminatory power of the
MLVA method. Indeed, in our study (exceeding the
ones reported here), we observed several different
genotypes that would have been assigned identical
when the non-integer alleles would have been ig-
nored by ‘rounding off’ their values using adjusted
and broadened binsets (results not shown).
There were some limitations in this study. First, as
no colometric agar plate was used for the screening
cultures, overgrowth of carbapenem-susceptible but
cefotaxime-resistant isolates could have led to over-
looking CNKP. However, all morphologically differ-
ent colonies were checked, and this was done by
trained and experienced microbiology technicians.
Colometric media are expensive, therefore, could not
be used in this study. Also, cefotaxime-susceptible
OXA-48-producing isolates could have been missed
with our screening method. Nevertheless, based on
the isolates found in the clinical cultures, it is un-
likely that these were playing a major role in the
epidemiology. Of note, the OXA-48 PCR was not
able to detect OXA-54 and OXA-436, but given the
results of the phenotypic detection method, and epi-
demiology in countries nearby, these are also not
suspected. Second, only two ICUs in one tertiary
care academic hospital participated, which does not
permit results to be called representative for all
ICUs in Indonesia. Third, the study was performed
more than 5 years ago, hence the epidemiology of
CNKP in Indonesia may be different now. Finally,
the limited rate of sampling of the environment and
of personnel (as opposed to patients) may have
undervalued their role in the chain of transmission
and acquisition of carbapenem-non-susceptible K.
pneumoniae.
Conclusions
In summary, this study is the largest to date that de-
scribes the characteristics and epidemiology of, and
outcome associated with carbapenem-non-susceptible
K. pneumoniae in ICUs in Indonesia. Colonization or
infection with carbapenem-non-susceptible K. pneu-
moniae during hospitalization was independently as-
sociated with prolonged LOS in the ICU, and may
affect survival during ICU stay. Prevention of
colonization by and infection from these multidrug-
resistant strains requires interventions directed to
source control and limiting the introduction and
transmission of such strains to and between patients.
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